Open Access
Numéro
Ann Toxicol Anal
Volume 20, Numéro 4, 2008
Page(s) 183 - 205
DOI https://doi.org/10.1051/ata/2009021
Publié en ligne 26 mars 2009
  1. Jiang HE et al. A new insight into Cannabis sativa (Cannabaceae) utilization from 2500-year-old Yanghai Tombs, Xinjiang, China. J Ethnopharmacol. 2006; 108(3): 414-422.
  2. Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007; 4(8): 1614-1648. [CrossRef] [PubMed]
  3. Small E. The forensic taxonomic debate on Cannabis: semantic hokum. J Forensic Sci. 1976; 21(2): 239-251. [PubMed]
  4. Mechoulam R. Marihuana chemistry. Science. 1970; 168(936): 1159-1166. [CrossRef] [PubMed]
  5. Giroud C. Analysis of cannabinolds in hemp plants. Chimia. 2002; 56(3): 80-83. [CrossRef]
  6. Toyota M, Shimamura T, Ishii H, Renner M, Braggins J, Asakawa Y. New bibenzyl cannabinoid from the New Zealand liverwort Radula marginata. Chem Pharm Bull (Tokyo). 2002; 50(10): 1390-1392. [CrossRef] [PubMed]
  7. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol–recent advances. Chem Biodivers. 2007; 4(8): 1678-1692. [CrossRef] [PubMed]
  8. Verhoeckx KC et al. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB(1) and CB(2) receptor coupled pathways. Int Immunopharmacol. 2006; 6(4): 656-665.
  9. Dussy FE, Hamberg C, Luginbuhl M, Schwerzmann T, Briellmann TA. Isolation of Delta9-THCA-A from hemp and analytical aspects concerning the determination of Delta9-THC in cannabis products. Forensic Sci Int. 2005; 149(1): 3-10. [CrossRef] [PubMed]
  10. elSohly MA, Jones AB. Drug testing in the workplace: could a positive test for one of the mandated drugs be for reasons other than illicit use of the drug? J Anal Toxicol. 1995; 19(6): 450-458.
  11. Novak J, Zitterl-Eglseer K, Deans SG, Franz CM. Essential oils of different cultivars of Cannabis sativa L. and their antimicrobial activity. Flav Frag J. 2001; 16: 259-262. [CrossRef]
  12. Stahl E, Kunde P. Die Leitsubstanzen der Haschisch-Suchhunde (Leading substances for hashish narcotic dogs). Kriminalistik. 1973; 9: 385-388.
  13. Oomah BD, Busson M, Godfrey DV, Drover JCG. Characteristics of hemp (Cannabis sativa L.) seed oil. Food Chemistry. 2002; 76: 33-43. [CrossRef]
  14. Taura F, Sirikantaramas S, Shoyama Y, Shoyama Y, Morimoto S. Phytocannabinoids in Cannabis sativa: recent studies on biosynthetic enzymes. Chem Biodivers. 2007; 4(8): 1649-1663. [CrossRef] [PubMed]
  15. Sirikantaramas S, Morimoto S, Shoyama Y, Ishikawa Y, Wada Y, Taura F. The gene controlling marijuana psychoactivity: molecular cloning and heterologous expression of Delta1-tetrahydrocannabinolic acid synthase from Cannabis sativa L. J Biol Chem. 2004; 279(38): 39767-39774. [CrossRef] [PubMed]
  16. Sirikantaramas S, Taura F, Morimoto S, Shoyama Y. Recent advances in Cannabis sativa research: biosynthetic studies and its potential in biotechnology. Curr Pharm Biotechnol. 2007; 8(4): 237-243. [CrossRef] [PubMed]
  17. Chaudry HR, Moss HB, Bashir A, Suliman T. Cannabis psychosis following bhang ingestion. Br J Addict. 1991; 86(9): 1075-1081. [CrossRef] [PubMed]
  18. Gupta BD, Jani CB, Shah PH. Fatal 'Bhang' poisoning. Med Sci Law. 2001; 41(4): 349-352. [PubMed]
  19. Andre C, Jaber-Filho JA, Bento RM, Damasceno LM, Aquino-Neto FR. Delirium following ingestion of marijuana present in chocolate cookies. CNS Spectr. 2006; 11(4): 262-264. [PubMed]
  20. Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther. 1996; 34(10): 446-452. [PubMed]
  21. Korf DJ, Benschop A, Wouters M. Differential responses to cannabis potency: a typology of users based on self-reported consumption behaviour. Int J Drug Policy. 2007; 18(3): 168-176. [CrossRef] [PubMed]
  22. Document consulté sur le site http://www.nida.nih.gov/ le 22 octobre 2008.
  23. Gorelick DA, Heishman SJ. Methods for clinical research involving cannabis administration. Methods Mol Med. 2006; 123: 235-253. [PubMed]
  24. Carter GT, Weydt P, Kyashna-Tocha M, Abrams DI. Medicinal cannabis: rational guidelines for dosing. IDrugs. 2004; 7(5): 464-470. [PubMed]
  25. Document consulté sur le site http://www.rivm.nl/ le 21 octobre 2008.
  26. Hunault CC et al. Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. Psychopharmacology (Berl). 2008; 201(2): 171-181.
  27. Mensinga TT et al. A double-blind, randomized, placebo-controlled, cross-over study on the pharmacokinetics and effects of cannabis. RIVM. 2006; 267002002: 1-52.
  28. Document consulté sur le site http://www.unodc.org/india/drug_report.html le 21 octobre 2008.
  29. Document consulté sur le site http://www.sfa-ispa.ch/DocUpload/d_consomm_cannabis.pdf le 21 octobre 2008.
  30. Muller S, Gmel G. Changes in the age of onset of cannabis use: results of the 2nd Swiss Health Survey 1997. Soz Praventivmed. 2002; 47(1): 14-23. [CrossRef] [PubMed]
  31. Document consulté sur le site http://www.bag.admin.ch/themen/drogen/ le 21 octobre 2008.
  32. Müller R et al. Cannabis, état des lieux en Suisse. 2004; ISPA/ISBN 2-88183-106-0: 1-80.
  33. Adamson SJ, Sellman JD. A prototype screening instrument for cannabis use disorder: the Cannabis Use Disorders Identification Test (CUDIT) in an alcohol-dependent clinical sample. Drug Alcohol Rev. 2003; 22(3): 309-315. [CrossRef] [PubMed]
  34. Piomelli D, Astarita G, Rapaka R. A neuroscientist's guide to lipidomics. Nat Rev Neurosci. 2007; 8(10): 743-754. [CrossRef] [PubMed]
  35. Pertwee RG. The diverse CB(1) and CB(2) receptor pharmacology of three plant cannabinoids: Delta(9)-tetrahydroca- nnabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin. Br J Pharmacol. 2008; 153(2): 199-215. [CrossRef] [PubMed]
  36. Mechoulam R, Hanus L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids. 2000; 108(1.2): 1-13.
  37. Di Marzo V. A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends Pharmacol Sci. 2006; 27(3): 134-140. [CrossRef] [PubMed]
  38. Russo EB, McPartland JM. Cannabis is more than simply delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl). 2003; 165(4): 431-432; author reply 433-434. [PubMed]
  39. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci. 2007; 8(11): 885-895. [CrossRef] [PubMed]
  40. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008; 153(2): 199-215. [CrossRef] [PubMed]
  41. Berdyshev EV. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids. 2000; 108(1-2): 169-190. [CrossRef] [PubMed]
  42. Onaivi ES. Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology. 2006; 54(4): 231-246. [CrossRef] [PubMed]
  43. Burstein S. PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life Sci. 2005; 77(14): 1674-1684. [CrossRef] [PubMed]
  44. Burstein SH, Karst M, Schneider U, Zurier RB. Ajulemic acid: A novel cannabinoid produces analgesia without a "high". Life Sci. 2004; 75(12): 1513-1522. [CrossRef] [PubMed]
  45. Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther. 2007; 114(1): 13-33. [CrossRef] [PubMed]
  46. Brown AJ. Novel cannabinoid receptors. Br J Pharmacol. 2007; 152(5): 567-575. [CrossRef] [PubMed]
  47. Hanus LO. Discovery and isolation of anandamide and other endocannabinoids. Chem Biodivers. 2007; 4(8): 1828-1841. [CrossRef] [PubMed]
  48. Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol. 2007; 18(2): 129-140. [CrossRef] [PubMed]
  49. Hashimotodani Y, Ohno-Shosaku T, Kano M. Endocannabinoids and synaptic function in the CNS. Neuroscientist. 2007; 13(2): 127-137. [CrossRef] [PubMed]
  50. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002; 296(5568): 678-682. [CrossRef] [PubMed]
  51. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992; 16(5): 276-282. [CrossRef] [PubMed]
  52. Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ. Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther. 1992; 52(1): 31-41. [CrossRef] [PubMed]
  53. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003; 42(4): 327-360. [CrossRef] [PubMed]
  54. Ménétrey A et al. Profils cinétiques du delta-9-tetrahydrocannabinol, du 11-hydroxy-delta-9-tétrahydroc- annabinol et de l'acide 11-nor-delta-9-tétrahydrocannabinol- 9-carboxylique chez le sujet volontaire sain après administration orale de décoctions de cannabis ou de dronabinol. Ann Toxicol Anal. 2004; 16(4): 231-243.
  55. Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol. 2005; (168): 657-690.
  56. Harvey DJ, Paton WDM. Metabolism of the cannabinoids. Rev Biochem Toxicol. 1984; 6: 221-264.
  57. Lemberger L, Crabtree RE, Rowe HM. 11-hydroxy-9-tetrahy- drocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science. 1972; 177(43): 62-64. [CrossRef] [PubMed]
  58. Kemp PM et al. Cannabinoids in humans. II. The influence of three methods of hydrolysis on the concentration of THC and two metabolites in urine. J Anal Toxicol. 1995; 19(5): 292-298. [CrossRef] [PubMed]
  59. Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol. 2005; 70(7): 1096-1103. [CrossRef] [PubMed]
  60. Giroud C et al. Impact of oral Cannabis on driving skills and genetic vulnerability to psychotic symptoms. Proceedings of the XV GTFCh Symposium, Aktuelle Beiträge zur Forensischen und klinischen Toxikologie, Mosbach, 2007. In: Pragst F, Aderjan R. 2008: 193-203.
  61. Spahn-Langguth H, Benet LZ. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev. 1992; 24(1): 5-47.
  62. Bradow G, Kan LS, Fenselau C. Studies of intramolecular rearrangements of acyl-linked glucuronides using salicylic acid, flufenamic acid, and (S)- and (R)-benoxaprofen and confirmation of isomerization in acyl-linked delta 9-11-carboxytetrahydrocannabinol glucuronide. Chem Res Toxicol. 1989; 2(5): 316-324. [CrossRef] [PubMed]
  63. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet. 1999; 36(6): 439-452. [CrossRef] [PubMed]
  64. Thomas A, Widmer C, Hopfgartner G, Staub C. Fast gas chromatography and negative-ion chemical ionization tandem mass spectrometry for forensic analysis of cannabinoids in whole blood. J Pharm Biomed Anal. 2007; 45(3): 495-503. [CrossRef] [PubMed]
  65. Jamey C, Szwarc E, Tracqui A, Ludes B. Determination of cannabinoids in whole blood by UPLC-MS-MS. J Anal Toxicol. 2008; 32(5): 349-354. [CrossRef] [PubMed]
  66. Menetrey A et al. Assessment of Driving Capability Through the Use of Clinical and Psychomotor Tests in Relation to Blood Cannabinoids Levels Following Oral Administration of 20 mg Dronabinol or of a Cannabis Decoction Made with 20 or 60 mg Delta9-THC. J Anal Toxicol. 2005; 29(5): 327-338.
  67. Giroud C, Menetrey A, Augsburger M, Buclin T, Sanchez-Mazas P, Mangin P. Delta(9)-THC, 11-OH-Delta(9)-THC and Delta(9)-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. Forensic Sci Int. 2001; 123(2-3): 159-164. [CrossRef] [PubMed]
  68. Garrett ER, Hunt CA. Physiochemical properties, solubility, and protein binding of delta9-tetrahydrocannabinol. J Pharm Sci. 1974; 63(7): 1056-1064. [CrossRef] [PubMed]
  69. Manno JE et al. Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9-tetrahydrocannabinol, 11-hydroxy- delta9-tetrahydrocannabinol, and 11-nor-delta9-tetrahyd- rocannabinol-9-carboxylic acid. J Anal Toxicol. 2001; 25(7): 538-549.
  70. Kauert GF, Ramaekers JG, Schneider E, Moeller MR, Toennes SW. Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. J Anal Toxicol. 2007; 31(5): 288-293. [CrossRef] [PubMed]
  71. Glaz-Sandberg A, Dietz L, Nguyen H, Oberwittler H, Aderjan R, Mikus G. Pharmacokinetics of 11-nor-9-Carboxy-Delta(9)-Tetrahydrocannabinol (CTHC) After Intravenous Administration of CTHC in Healthy Human Subjects. Clin Pharmacol Ther. 2007; 82(1): 63-69. [CrossRef] [PubMed]
  72. Huestis MA, Barnes A, Smith ML. Estimating the Time of Last Cannabis Use from Plasma {Delta}9-Tetrahydrocannabinol and 11-nor-9-Carboxy-{Delta}9-Tetrahydrocannabinol Con- centrations. Clin Chem. 2005; 51(12): 2289-2295. [CrossRef] [PubMed]
  73. Martin CS, Kaczynski NA, Maisto SA, Tarter RE. Polydrug use in adolescent drinkers with and without DSM-IV alcohol abuse and dependence. Alcohol Clin Exp Res. 1996; 20(6): 1099-1108. [CrossRef] [PubMed]
  74. Agosti V, Nunes E, Levin F. Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependence. Am J Drug Alcohol Abuse. 2002; 28(4): 643-652. [CrossRef] [PubMed]
  75. Oscar-Berman M, Marinkovic K. Alcoholism and the brain: an overview. Alcohol Res Health. 2003; 27(2): 125-133. [PubMed]
  76. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol. 1999; 58(4): 315-348. [CrossRef] [PubMed]
  77. Schneider M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol. 2008; 13(2): 253-263. [CrossRef] [PubMed]
  78. Crews FT, Mdzinarishvili A, Kim D, He J, Nixon K. Neurogenesis in adolescent brain is potently inhibited by ethanol. Neuroscience. 2006; 137(2): 437-445. [CrossRef] [PubMed]
  79. Medina KL, Hanson KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF. Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. J Int Neuropsychol Soc. 2007; 13(5): 807-820. [CrossRef] [PubMed]
  80. Robbe D, Montgomery SM, Thome A, Rueda-Orozco PE, McNaughton BL, Buzsaki G. Cannabinoids reveal importance of spike timing coordination in hippocampal function. Nat Neurosci. 2006; 9(12): 1526-1533. [CrossRef] [PubMed]
  81. Robinson TE, Berridge KC. Review. The incentive sensitization theory of addiction: some current issues. Philos Trans R Soc Lond B Biol Sci. 2008; 363(1507): 3137-3146. [CrossRef] [PubMed]
  82. Berridge KC. Pleasures of the brain. Brain Cogn. 2003; 52(1): 106-128. [CrossRef] [PubMed]
  83. Basavarajappa BS. The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism. Mini Rev Med Chem. 2007; 7(8): 769-779. [CrossRef] [PubMed]
  84. Solinas M, Yasar S, Goldberg SR. Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res. 2007; 56(5): 393-405. [CrossRef] [PubMed]
  85. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006; 29(4): 225-232. [CrossRef] [PubMed]
  86. Fattore L, Fadda P, Spano MS, Pistis M, Fratta W. Neurobiological mechanisms of cannabinoid addiction. Mol Cell Endocrinol. 2008; 286(1-2): S97-S107. [CrossRef] [PubMed]
  87. Valjent E, Mitchell JM, Besson MJ, Caboche J, Maldonado R. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol. 2002; 135(2): 564-578. [CrossRef] [PubMed]
  88. Foltin RW, Fischman MW, Levin FR. Cardiovascular effects of cocaine in humans: laboratory studies. Drug Alcohol Depend. 1995; 37(3): 193-210. [CrossRef] [PubMed]
  89. Giroud C et al. A fatal overdose of cocaine associated with coingestion of marijuana, buprenorphine, and fluoxetine. Body fluid and tissue distribution of cocaine and its metabolites determined by hydrophilic interaction chromatography-mass spectrometry(HILIC-MS). J Anal Toxicol. 2004; 28(6): 464-474. [CrossRef] [PubMed]
  90. Robledo P, Berrendero F, Ozaita A, Maldonado R. Advances in the field of cannabinoid–opioid cross-talk. Addict Biol. 2008; 13(2): 213-224. [CrossRef] [PubMed]
  91. Sirikantaramas S, Taura F, Tanaka Y, Ishikawa Y, Morimoto S, Shoyama Y. Tetrahydrocannabinolic acid synthase, the enzyme controlling marijuana psychoactivity, is secreted into the storage cavity of the glandular trichomes. Plant Cell Physiol. 2005; 46(9): 1578-1582. [CrossRef] [PubMed]
  92. Morimoto S et al. Identification and characterization of cannabinoids that induce cell death through mitochondrial permeability transition in Cannabis leaf cells. J Biol Chem. 2007; 282(28): 20739-20751.
  93. Thompson GR, Fleischman RW, Rosenkrantz H, Braude MC. Oral and intravenous toxicity of delta9-tetrahydrocannabinol in rhesus monkeys. Toxicol Appl Pharmacol. 1974; 27(3): 648-665. [CrossRef] [PubMed]
  94. Thompson GR, Rosenkrantz H, Schaeppi UH, Braude MC. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. Toxicol Appl Pharmacol. 1973; 25(3): 363-372. [CrossRef] [PubMed]
  95. Bowman M, Pihl RO. Cannabis: psychological effects of chronic heavy use. A controlled study of intellectual functioning in chronic users of high potency cannabis. Psychopharmacologia. 1973; 29(2): 159-170. [CrossRef] [PubMed]
  96. Boros CA, Parsons DW, Zoanetti GD, Ketteridge D, Kennedy D. Cannabis cookies: a cause of coma. J Paediatr Child Health. 1996; 32(2): 194-195. [CrossRef] [PubMed]
  97. Exley C, Begum A, Woolley MP, Bloor RN. Aluminum in tobacco and cannabis and smoking-related disease. Am J Med. 2006; 119(3): 276 279-211. [CrossRef]
  98. Hazekamp A, Sijrier P, Verpoorte R, Bender J, Van Bakel N. Cannabis uit de apotheek is beter: Vergelijking van prijs, dronabinolgehalte en microbiologische kwaliteit. Pharmaceutisch Weekblad. 2005; 140(12): 402-405.
  99. Rosenstreich DL, Moday HJ, Hudes G. Asthma and the environment. J Asthma. 2003; 40: S23-S29.
  100. Mathew RJ, Wilson WH, Turkington TG, Coleman RE. Cerebellar activity and disturbed time sense after THC. Brain Res. 1998; 797(2): 183-189. [CrossRef] [PubMed]
  101. Khalsa JH, Genser S, Francis H, Martin B. Clinical consequences of marijuana. J Clin Pharmacol. 2002; 42(11): S7-S10. [CrossRef]
  102. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001; 178: 101-106. [CrossRef] [PubMed]
  103. Pope HG, Jr., Gruber AJ, Yurgelun-Todd D. The residual neuropsychological effects of cannabis: the current status of research. Drug Alcohol Depend. 1995; 38(1): 25-34. [CrossRef] [PubMed]
  104. Heishman SJ, Huestis MA, Henningfield JE, Cone EJ. Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures. Pharmacol Biochem Behav. 1990; 37(3): 561-565. [CrossRef] [PubMed]
  105. Schwartz RH, Gruenewald PJ, Klitzner M, Fedio P. Short-term memory impairment in cannabis-dependent adolescents. Am J Dis Child. 1989; 143(10): 1214-1219. [PubMed]
  106. D'Souza DC et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004; 29(8): 1558-1572.
  107. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev. 1986; 38(2): 151-178. [PubMed]
  108. Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth. 1999; 83(4): 637-649. [CrossRef] [PubMed]
  109. Favrat B et al. Two cases of "cannabis acute psychosis" following the administration of oral cannabis. BMC Psychiatry. 2005; 5(1): 17.
  110. Heishman SJ, Stitzer ML, Yingling JE. Effects of tetrahydrocannabinol content on marijuana smoking behavior, subjective reports, and performance. Pharmacol Biochem Behav. 1989; 34(1): 173-179. [CrossRef] [PubMed]
  111. Fride E. Endocannabinoids in the central nervous system–an overview. Prostaglandins Leukot Essent Fatty Acids. 2002; 66(2-3): 221-233. [CrossRef] [PubMed]
  112. Ashton JC, Smith PF, Darlington CL. The effect of delta 9-tetrahydrocannabinol on the extinction of an adverse associative memory. Pharmacology. 2008; 81(1): 18-20. [CrossRef] [PubMed]
  113. Soltesz I, Staley K. High times for memory: cannabis disrupts temporal coordination among hippocampal neurons. Nat Neurosci. 2006; 9(12): 1461-1463. [CrossRef] [PubMed]
  114. Lutz B. The endocannabinoid system and extinction learning. Mol Neurobiol. 2007; 36(1): 92-101. [CrossRef] [PubMed]
  115. Aryana A, Williams MA. Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? Int J Cardiol. 2007; 118(2): 141-144.
  116. Mathew RJ, Wilson WH, Davis R. Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics. Pharmacol Biochem Behav. 2003; 75(2): 309-318. [CrossRef] [PubMed]
  117. Batkai S et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation. 2004; 110(14): 1996-2002.
  118. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001; 103(23): 2805-2809. [CrossRef] [PubMed]
  119. Lindsay AC, Foale RA, Warren O, Henry JA. Cannabis as a precipitant of cardiovascular emergencies. Int J Cardiol. 2005; 104(2): 230-232. [CrossRef] [PubMed]
  120. Rezkalla SH, Sharma P, Kloner RA. Coronary no-flow and ventricular tachycardia associated with habitual marijuana use. Ann Emerg Med. 2003; 42(3): 365-369. [CrossRef] [PubMed]
  121. Bachs L, Morland H. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int. 2001; 124(2-3): 200-203. [CrossRef] [PubMed]
  122. Document consulté sur le site http://www.systemstech.com/content/view/29/39/ le 21 octobre 2008.
  123. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR. High-Potency Marijuana Impairs Executive Function and Inhibitory Motor Control. Neuropsychopharmacology. 2006.
  124. Cadet JL, Bolla K, Herning RI. Neurological assessments of marijuana users. Methods Mol Med. 2006; 123: 255-268. [PubMed]
  125. Saugy M et al. Cannabis and sport. Br J Sports Med. 2006; 40(1): S13-S15.
  126. Block RI, Farinpour R, Braverman K. Acute effects of marijuana on cognition: relationships to chronic effects and smoking techniques. Pharmacol Biochem Behav. 1992; 43(3): 907-917. [CrossRef] [PubMed]
  127. Brook JS, Adams RE, Balka EB, Johnson E. Early adolescent marijuana use: risks for the transition to young adulthood. Psychol Med. 2002; 32(1): 79-91. [CrossRef] [PubMed]
  128. Lynskey M, Hall W. The effects of adolescent cannabis use on educational attainment: a review. Addiction. 2000; 95(11): 1621-1630. [CrossRef] [PubMed]
  129. Tolmunen T et al. Dissociation in a general population of Finnish adolescents. J Nerv Ment Dis. 2007; 195(7): 614-617.
  130. Berghuis P et al. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science. 2007; 316(5828): 1212-1216.
  131. Harkany T, Guzman M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K. The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci. 2007; 28(2): 83-92. [CrossRef] [PubMed]
  132. Ferraro DP. Acute effects of marijuana on human memory and cognition. NIDA Res Monogr. 1980; 31: 98-119. [PubMed]
  133. Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl). 2006; 188(4): 425-444. [CrossRef] [PubMed]
  134. Wolfling K, Flor H, Grusser SM. Psychophysiological responses to drug-associated stimuli in chronic heavy cannabis use. Eur J Neurosci. 2008; 27(4): 976-983. [CrossRef] [PubMed]
  135. Fergusson DM, Poulton R, Smith PF, Boden JM. Cannabis and psychosis. BMJ. 2006; 332(7534): 172-175. [CrossRef] [PubMed]
  136. Wallace C, Mullen PE, Burgess P. Criminal offending in schizophrenia over a 25-year period marked by deinstitutionalization and increasing prevalence of comorbid substance use disorders. Am J Psychiatry. 2004; 161(4): 716-727. [CrossRef] [PubMed]
  137. Howard RC, Menkes DB. Brief report: changes in brain function during acute cannabis intoxication: preliminary findings suggest a mechanism for cannabis-induced violence. Crim Behav Ment Health. 2007; 17(2): 113-117. [CrossRef] [PubMed]
  138. Haggard-Grann U, Hallqvist J, Langstrom N, Moller J. The role of alcohol and drugs in triggering criminal violence: a case-crossover study*. Addiction. 2006; 101(1): 100-108. [CrossRef] [PubMed]
  139. Michon JA. Explanatory pitfalls and rule-based driver models. Accid Anal Prev. 1989; 21(4): 341-353. [CrossRef] [PubMed]
  140. Menetrey A, Augsburger M, Giroud C, Mangin P. Cannabis and automobile driving. Schweiz Rundsch Med Prax. 2001; 90(34): 1398-1407.
  141. Augsburger M et al. Concentration of drugs in blood of suspected impaired drivers. Forensic Sci Int. 2005; 153(1): 11-15.
  142. Giroud C et al. Effects of oral cannabis and dronabinol on driving capacity. Ann Pharm Fr. 2006; 64(3): 161-172.
  143. Drummer OH et al. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid Anal Prev. 2004; 36(2): 239-248.
  144. Smiley AM. Marijuana: On road and driving simulator studies. Alcohol, Drugs and Driving: Abstracts and Reviews. 1986; 2: 121-134.
  145. Skopp G, Richter B, Potsch L. Serum cannabinoid levels 24 to 48 hours after cannabis smoking. Arch Kriminol. 2003; 212(3-4): 83-95. [PubMed]
  146. Grotenhermen F et al. Developing limits for driving under cannabis. Addiction. 2007; 102(12): 1910-1917.
  147. Jones AW, Holmgren A, Kugelberg FC. Driving under the influence of cannabis: a 10-year study of age and gender differences in the concentrations of tetrahydrocannabinol in blood. Addiction. 2008; 103(3): 452-461. [CrossRef] [PubMed]
  148. Azorlosa JL, Heishman SJ, Stitzer ML, Mahaffey JM. Marijuana smoking: effect of varying delta 9-tetrahydrocannabinol content and number of puffs. J Pharmacol Exp Ther. 1992; 261(1): 114-122. [PubMed]
  149. Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G. Cognition and motor control as a function of Delta(9)-THC concentration in serum and oral fluid: Limits of impairment. Drug Alcohol Depend. 2006; 85(2): 114-122. [CrossRef] [PubMed]
  150. Mathew RJ, Wilson WH, Humphreys D, Lowe JV, Weithe KE. Depersonalization after marijuana smoking. Biol Psychiatry. 1993; 33(6): 431-441. [CrossRef] [PubMed]
  151. Rafaelsen L, Christrup H, Bech P, Rafaelsen OJ. Effects of cannabis and alcohol on psychological tests. Nature. 1973; 242(5393): 117-118. [CrossRef] [PubMed]
  152. Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit. 2004; 26(2): 200-205. [CrossRef] [PubMed]
  153. Pehrsson A, Gunnar T, Engblom C, Seppa H, Jama A, Lillsunde P. Roadside oral fluid testing: Comparison of the results of Drugwipe 5 and Drugwipe Benzodiazepines on-site tests with laboratory confirmation results of oral fluid and whole blood. Forensic Sci Int. 2008; 175(2-3): 140-148. [CrossRef] [PubMed]
  154. Drummer OH, Gerostamoulos D, Chu M, Swann P, Boorman M, Cairns I. Drugs in oral fluid in randomly selected drivers. Forensic Sci Int. 2007; 170(2-3): 105-110. [CrossRef] [PubMed]
  155. Skopp G, Strohbeck-Kuehner P, Mann K, Hermann D. Deposition of cannabinoids in hair after long-term use of cannabis. Forensic Sci Int. 2007; 170(1): 46-50. [CrossRef] [PubMed]
  156. Huestis MA et al. Excretion of Delta(9)-tetrahydrocannabinol in sweat. Forensic Sci Int. 2007.
  157. Bar-Oz B, Klein J, Karaskov T, Koren G. Comparison of meconium and neonatal hair analysis for detection of gestational exposure to drugs of abuse. Arch Dis Child Fetal Neonatal Ed. 2003; 88(2): F98-F100. [CrossRef] [PubMed]
  158. Hayden JW. Passive inhalation of marijuana smoke: a critical review. J Subst Abuse. 1991; 3(1): 85-90. [CrossRef] [PubMed]
  159. Leson G, Pless P, Grotenhermen F, Kalant H, ElSohly MA. Evaluating the impact of hemp food consumption on workplace drug tests. J Anal Toxicol. 2001; 25(8): 691-698. [CrossRef] [PubMed]
  160. Niedbala RS, Kardos KW, Fritch DF, Kunsman KP, Blum KA, Newland GA et al. Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle. J Anal Toxicol. 2005; 29(7): 607-615. [CrossRef] [PubMed]
  161. Thorspecken J, Skopp G, Potsch L. In vitro contamination of hair by marijuana smoke. Clin Chem. 2004; 50(3): 596-602. [CrossRef] [PubMed]
  162. Raphael B, Wooding S, Stevens G, Connor J. Comorbidity: cannabis and complexity. J Psychiatr Pract. 2005; 11(3): 161-176. [CrossRef] [PubMed]
  163. Dannon PN, Lowengrub K, Amiaz R, Grunhaus L, Kotler M. Comorbid cannabis use and panic disorder: short term and long term follow-up study. Hum Psychopharmacol. 2004; 19(2): 97-101. [CrossRef] [PubMed]
  164. Kintz P. Bioanalytical procedures for detection of chemical agents in hair in the case of drug-facilitated crimes. Anal Bioanal Chem. 2007; 388(7): 1467-1474. [CrossRef] [PubMed]
  165. Martin BR. Role of lipids and lipid signaling in the development of cannabinoid tolerance. Life Sci. 2005; 77(14): 1543-1558. [CrossRef] [PubMed]
  166. Gonzalez S, Cebeira M, Fernandez-Ruiz J. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol Biochem Behav. 2005; 81(2): 300-318. [CrossRef] [PubMed]
  167. Sim-Selley LJ, Martin BR. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl] pyrrolo[1,2,3-de]-1,4-b enzoxazinyl]-(1-naphthalenyl)meth- anone mesylate (WIN55,212-2) or delta(9)- tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther. 2002; 303(1): 36-44. [CrossRef] [PubMed]
  168. Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci. 1976; 282: 221-239. [CrossRef] [PubMed]
  169. Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW. Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. Psychopharmacology (Berl). 2002; 164(4): 407-415. [CrossRef] [PubMed]
  170. Chang L, Chronicle EP. Functional imaging studies in cannabis users. Neuroscientist. 2007; 13(5): 422-432. [CrossRef] [PubMed]
  171. DeLisi LE. The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? Curr Opin Psychiatry. 2008; 21(2): 140-150.
  172. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002; 325(7374): 1199. [CrossRef] [PubMed]
  173. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987; 2(8574): 1483-1486. [CrossRef] [PubMed]
  174. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007; 370(9584): 319-328. [CrossRef] [PubMed]
  175. Hall W, Degenhardt L, Teesson M. Cannabis use and psychotic disorders: an update. Drug Alcohol Rev. 2004; 23(4): 433-443. [CrossRef] [PubMed]
  176. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM. Gene-Environment Interplay Between Cannabis and Psychosis. Schizophr Bull. 2008.
  177. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull. 2005; 31(3): 608-612. [CrossRef] [PubMed]
  178. Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry. 2001; 158(12): 2033-2037. [CrossRef] [PubMed]
  179. Lane SD, Cherek DR, Pietras CJ, Steinberg JL. Performance of heavy marijuana-smoking adolescents on a laboratory measure of motivation. Addict Behav. 2005; 30(4): 815-828. [CrossRef] [PubMed]
  180. Lane SD, Cherek DR, Tcheremissine OV, Steinberg JL, Sharon JL. Response perseveration and adaptation in heavy marijuana-smoking adolescents. Addict Behav. 2007; 32(5): 977-990. [CrossRef] [PubMed]
  181. Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction. 2006; 101(4): 556-569. [CrossRef] [PubMed]
  182. Van Hoozen BE, Cross CE. Marijuana. Respiratory tract effects. Clin Rev Allergy Immunol. 1997; 15(3): 243-269. [CrossRef] [PubMed]
  183. Nowlan R, Cohen S. Tolerance to marijuana: heart rate and subjective "high" Clin Pharmacol Ther. 1977; 22(5): 550-556.
  184. Mateo I, Pinedo A, Gomez-Beldarrain M, Basterretxea JM, Garcia-Monco JC. Recurrent stroke associated with cannabis use. J Neurol Neurosurg Psychiatry. 2005; 76(3): 435-437. [CrossRef] [PubMed]
  185. White D, Martin D, Geller T, Pittman T. Stroke associated with marijuana abuse. Pediatr Neurosurg. 2000; 32(2): 92-94. [CrossRef] [PubMed]
  186. Tashkin DP. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis. 2005; 63(2): 93-100. [PubMed]
  187. Zhang ZF, Morgenstern H, Spitz MR, Tashkin DP, Yu GP, Marshall JR et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 1999; 8(12): 1071-1078. [PubMed]
  188. Bifulco M, Laezza C, Pisanti S, Gazzerro P. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol. 2006; 148(2): 123-135. [CrossRef] [PubMed]
  189. Lynskey MT et al. Major depressive disorder, suicidal ideation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use. Arch Gen Psychiatry. 2004; 61(10): 1026-1032.
  190. Fried PA, O'Connell CM, Watkinson B. 60- and 72-month follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol: cognitive and language assessment. J Dev Behav Pediatr. 1992; 13(6): 383-391. [CrossRef] [PubMed]
  191. Fried PA, Smith AM. A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicol Teratol. 2001; 23(1): 1-11. [CrossRef] [PubMed]
  192. Porath AJ, Fried PA. Effects of prenatal cigarette and marijuana exposure on drug use among offspring. Neurotoxicol Teratol. 2005; 27(2): 267-277. [CrossRef] [PubMed]
  193. Daldrup T, Käferstein H, Köhler H, Maier R-D, Musshoff F. Deciding between one off/occasional and regular cannabis consumption. BlutAlkohol. 2000; 37: 39-47.
  194. Hart CL. Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies. Drug Alcohol Depend. 2005; 80(2): 147-159. [CrossRef] [PubMed]
  195. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the national comorbidity survey. Exp Clin Psychopharmacol. 1994; 2: 244-268. [CrossRef]
  196. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry. 2006; 19(3): 233-238. [CrossRef] [PubMed]
  197. Vandrey R, Budney AJ, Kamon JL, Stanger C. Cannabis withdrawal in adolescent treatment seekers. Drug Alcohol Depend. 2005; 78(2): 205-210. [CrossRef] [PubMed]
  198. Chen CY, O'Brien MS, Anthony JC. Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000-2001. Drug Alcohol Depend. 2005; 79(1): 11-22. [CrossRef] [PubMed]
  199. McRae AL, Budney AJ, Brady KT. Treatment of marijuana dependence: a review of the literature. J Subst Abuse Treat. 2003; 24(4): 369-376. [CrossRef] [PubMed]
  200. Gantner A. Multidimensional family therapy for adolescent clients with cannabis use disorders–Results and experience from the INCANT pilot study. Prax Kinderpsychol Kinderpsychiatr. 2006; 55(7): 520-532. [PubMed]
  201. Huestis MA et al. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl). 2007; 194(4): 505-515.
  202. Benyamina A, Lecacheux M, Blecha L, Reynaud M, Lukasiewcz M. Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence. Expert Rev Neurother. 2008; 8(3): 479-491. [CrossRef] [PubMed]
  203. Wilson DM, Varvel SA, Harloe JP, Martin BR, Lichtman AH. SR 141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice. Pharmacol Biochem Behav. 2006; 85(1): 105-113. [CrossRef] [PubMed]
  204. McCarberg BH, Barkin RL. The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview. Am J Ther. 2007; 14(5): 475-483. [CrossRef] [PubMed]
  205. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Pain. 2007.
  206. Document consulté sur le site http://www.cannabis-med.org/ le 21 octobre 2008.
  207. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol. 2006; 105(1-2): 1-25. [CrossRef] [PubMed]
  208. Hanus LO. Pharmacological and therapeutic secrets of plant and brain (Endo)cannabinoids. Med Res Rev. 2008.
  209. Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2008; 29(2): 192-200.
  210. Mechoulam R. Plant cannabinoids: a neglected pharmacological treasure trove. Br J Pharmacol. 2005; 146(7): 913-915. [CrossRef] [PubMed]
  211. Despres JP, Van Gaal L, Pi-Sunyer X, Scheen A. Efficacy and safety of the weight-loss drug rimonabant. Lancet. 2008; 371(9612): 555; author reply 556-557. [CrossRef]
  212. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007; 370(9600): 1706-1713. [CrossRef] [PubMed]
  213. Mallat A, Teixeira-Clerc F, Deveaux V, Lotersztajn S. Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin Ther Targets. 2007; 11(3): 403-409. [CrossRef] [PubMed]
  214. Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 2002; 42(11): S11-S19. [CrossRef]
  215. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci. 2006; 95(6): 1308-1317. [CrossRef] [PubMed]
  216. Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother. 2006; 7(5): 607-615. [CrossRef] [PubMed]
  217. Wilkinson JD et al. Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects? J Pharm Pharmacol. 2003; 55(12): 1687-1694.
  218. Stebulis JA, Johnson DR, Rossetti RG, Burstein SH, Zurier RB. Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells. Life Sci. 2008.
  219. Wilkins MR. Cannabis and cannabis-based medicines: potential benefits and risks to health. Clin Med. 2006; 6(1): 16-18. [CrossRef] [PubMed]
  220. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol. 2003; 2(5): 291-298. [CrossRef] [PubMed]
  221. Wallace M et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiologiy. 2007; 107(5): 785-796.
  222. Martin BR et al. Pharmacological characterization of novel water-soluble cannabinoids. J Pharmacol Exp Ther. 2006; 318(3): 1230-1239.
  223. Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N. `Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom. (in press).
  224. Huffman JW et al. Structure-activity relationships for Formula ,Formula -dimethylalkyl-Delta8-tetrahydrocannabinols. Bioorg Med Chem. 2003; 11(7): 1397-1410. [CrossRef] [PubMed]
  225. Huffman JW, Thompson AL, Wiley JL, Martin BR. Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008; 16(1): 322-335. [CrossRef] [PubMed]
  226. Monnet-Tschudi F et al. Delta-9-tetrahydrocannabinol accumulation, metabolism and cell-type-specific adverse effects in aggregating brain cell cultures. Toxicol Appl Pharmacol. 2008; 228(1): 8-16.
  227. Auwarter V. “SPICE” sowie weitere Räuchermischungen enthalten Designer-Cannabinoid. Toxichem + Krimtech. 2008; 75(3): 127-129.
  228. Thomas A, Hopfgartner G, Giroud C, Staub C. Quantitative and qualitative profiling of endocannabinoids in human plasma using a triple quadrupole linear ion trap mass spectrometer with liquid chromatography. Rapid Commun Mass Spectrom. 2009; 23(5): 629-638. [CrossRef] [MathSciNet] [PubMed]